Global HIV Drug Market

The Global HIV Drug market size was valued at US$ 25.1 Billion in 2020 and projected to reach US$ 35.3 Billion by 2027, growing at a CAGR of 3.2% during the forecast period, 2021-2027. The rising prevalence of HIV and its diagnosis is one of the key factors driving the global HIV medications market forward. A surge in government efforts to raise public awareness about causes, symptoms, and treatments also impacts the market. Furthermore, the emergence of generic pharmaceuticals, which are less expensive and chemically identical to branded treatments, contributes to the demand for HIV medications. Moreover, the global HIV medicine industry has benefited from the novel coronavirus outbreak. COVID-19 infections are treated with HIV medicines that have been repurposed. Several nations are now evaluating and employing antiretroviral medications to treat coronavirus infections (for example, lopinavir enhanced with ritonavir (LPV/r). Furthermore, the increasing HIV cases among young people because of lack of awareness and unprotected sexual practices increase the use of HIV drugs practically.

What is the Global HIV Drug Market?

Sales of Human Immunodeficiency Virus (HIV) medications used to treat HIV/AIDS make up the HIV drug industry. Antiretroviral drug companies that manufacture antiretroviral drugs such as nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, entry and fusion inhibitors, integrase inhibitors, and protease inhibitors for the treatment of HIV infection generate revenue in this market.

Growth Driver

Increased Number of Infection Cases

The expansion of the worldwide HIV medications market has been encouraged by increasing the number of HIV-infected people worldwide. The growing frequency of HIV infections, especially among the youth, is due to unprotected sexual practices, exposure to needles or syringes contaminated with infected body fluids or tissues. The various government initiatives to improve awareness. Furthermore, introducing generic medications, which are less expensive and chemically identical to branded drugs, aided market expansion. However, the industry is hampered by stringent regulatory requirements for the approval and sale of HIV medications. The increase in the number of items in the pipeline, on the other hand, is projected to provide lucrative chances for market participants in the future.

Pre Covid-19 impact

Factors such as the rise in government initiatives for HIV drugs and economically and technologically advanced market players drive the market growth for the global HIV drug market. Before the covid 19 breakdown thing was normal, the governments in their respective countries focused more on HIV treatment. Specifically, continuous research was the means to some important innovations.

Covid-19 impact

The demand for HIV drugs was impeded by the shutdown of land and air transport systems, suppliers’ failure to provide drugs on time, and reduced access to health facilities inside countries owing to the pandemic. Furthermore, the rescheduling of HIV treatment processes has resulted in a potential backlog of patients. Lockdown affected testing and antiretroviral treatment. On the other hand, drugs that were primarily used for the treatment of HIV started for treating covid patients, which in turn exaggerated the demand for HIV drugs.

Post Covid-19 impact

On the other hand, some governments have permitted the reopening of private HIV clinics as long as they adhere to social distancing regulations. Covid-19 affects individuals living with HIV (PWH) in unique ways and will continue to impact HIV research and therapy after the covid-19 crisis. HIV testing got decreased by a huge number during and after the covid 19 pandemic. Diagnostic services also got affected, and deaths from infections got increased.

Type Segmental Analysis

Based on the types, the Global HIV Drug Market is segregated into Protease Inhibitors, HIV Integrase Strand Transfer Inhibitors, Multi-Class Combination medications, Non-Nucleoside Reverse Transcriptase Inhibitors (NRTI), Entry Inhibitors — CCR5 Co-Receptor Antagonist, Fusion Inhibitors and Others). The Multi-Class Combination medications are expected to lead the market by 2027. The sector has the biggest market share because the multi-class combination medications incorporate the most modern technique for treating HIV infection. This is also due to a growth in the use of medications from this prescription class, which have superior results in the control of HIV and related co-infections and are easier to use and attach.

Application Segmental Analysis

The global HIV Drug Market is segregated into retail pharmacies, hospital pharmacies, online pharmacies, and others based on the application. The hospital pharmacies currently hold the account for the largest share in the global HIV Drug market. It is owing to the purpose of a hospital is to provide patients with diagnostic and treatment services. The use of pharmaceuticals is an important aspect of patient treatment. Pharmacists and nurses work together to ensure that drugs are used appropriately in hospitals.

Region Segmental Analysis

The global HIV drug market is segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. North America is the most promising market accounting for the majority of the global HIV drug market. North America has the biggest market share in 2020, owing to a growth in the number of HIV-positive people, advancements in HIV therapy, and increased government financing for drug R&D. Furthermore, Asia-Pacific is predicted to have the highest development potential due to key companies’ focus on rising economies, particularly on people’s health with improved treatment for various diseases and an increase in the incidence of HIV infection.

Competitor Analysis

Companies include Bristol-Myers squibb, Gilead Sciences, Glaxcosmithkline, Jhonson & Jhonson, Merck, Cipla, Pfizer Inc, Abbvie are the key players in the global personalized learning market.

key stakeholders

• Market research and consulting firms
• Industry Associations
• Global drug manufacturing firms
• Research Organizations and consulting companies
• Organizations, associations, and alliances related to HIV drug manufacturing
• Regulatory Bodies
• Suppliers
• Retailers

Recent Developments

• Cabenuva was approved by FDA on Jan 2021, along with the oral form of cabotegravir, which is expected to be taken for a month with an oral version of rilpivirine before starting cabenuva treatment to see how patients react to the two-medication combination.
• In June 2021, the rising development of antiretroviral therapy makes it the first long-acting injectable formulation and a long-acting suppression are expected to boost the worldwide HIV medications market (ATLAS). Physicians frequently believe that the ATLAS regimen will effectively enhance compliance rates and offer a once-a-month dosing form.